Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)

McMaster University

$100,000.00

Structural Basis of Aberrant cAMP Signaling and of PKA-Targeting Therapies

FY 2023-24

Summary
Protein Kinase A (PKA) plays a key role in controlling cellular metabolism. Genetic PKA mutations impair its ability to regulate cells, resulting in a general predisposition for pancreatic, endocrine, and cardiac tumors, as well as developmental disorders associated with intellectual disabilities and abnormal bone growth. We plan to study how disease-causing mutations alter PKA regulation. PKA also offers therapeutic opportunities for lung diseases, including cystic fibrosis (CF). CF is caused by the defective functioning of a molecule called the CF transmembrane conductance regulator (CFTR). When CFTR functions properly, mucus is cleared promptly from the lungs, but when it does not work correctly because of inherited defects, sticky mucus accumulates in the lungs, making breathing difficult. A promising way to counter the effects of CFTR variations is to modify CFTR through a chemical reaction called phosphorylation. However, current methods to phosphorylate CFTR result in widespread side effects that significantly decrease the quality of life of CF patients. One way to circumvent these adverse side effects is selectively displacing proteins that prevent CFTR phosphorylation. A molecule capable of this displacement has been identified but is not very stable in the body. To convert it into a stable drug with few side effects, it is essential to understand how this 'displacing' molecule works at the atomic level. For this purpose, we plan to determine the structure of the complex formed by this molecule and its receptor protein, PKA, and to understand how this structure explains the 'displacing' function of this molecule. Overall, the proposed research will explain the molecular mechanisms of multiple tumors and pediatric disorders, and will facilitate the design of new drugs that restore the function of defective PKA and CFTR with fewer side effects than currently available treatments.
Program
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495044
Name
Melacini Giuseppe
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Genetics
Theme2
Biomedical
Prcname2
Biochemistry & Molecular Biology - A
Projecttitle
Structural Basis of Aberrant cAMP Signaling and of PKA-Targeting Therapies
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Acrodysostosis; Allostery; Camp; Carney Complex; Cystic Fibrosis; Dynamics; Nuclear Magnetic Resonance (Nmr); Protein Kinase A; Signaling
Abstract
Protein Kinase A (PKA) plays a key role in controlling cellular metabolism. Genetic PKA mutations impair its ability to regulate cells, resulting in a general predisposition for pancreatic, endocrine, and cardiac tumors, as well as developmental disorders associated with intellectual disabilities and abnormal bone growth. We plan to study how disease-causing mutations alter PKA regulation. PKA also offers therapeutic opportunities for lung diseases, including cystic fibrosis (CF). CF is caused by the defective functioning of a molecule called the CF transmembrane conductance regulator (CFTR). When CFTR functions properly, mucus is cleared promptly from the lungs, but when it does not work correctly because of inherited defects, sticky mucus accumulates in the lungs, making breathing difficult. A promising way to counter the effects of CFTR variations is to modify CFTR through a chemical reaction called phosphorylation. However, current methods to phosphorylate CFTR result in widespread side effects that significantly decrease the quality of life of CF patients. One way to circumvent these adverse side effects is selectively displacing proteins that prevent CFTR phosphorylation. A molecule capable of this displacement has been identified but is not very stable in the body. To convert it into a stable drug with few side effects, it is essential to understand how this 'displacing' molecule works at the atomic level. For this purpose, we plan to determine the structure of the complex formed by this molecule and its receptor protein, PKA, and to understand how this structure explains the 'displacing' function of this molecule. Overall, the proposed research will explain the molecular mechanisms of multiple tumors and pediatric disorders, and will facilitate the design of new drugs that restore the function of defective PKA and CFTR with fewer side effects than currently available treatments.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Melacini, Giuseppe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
McMaster University - $100,000 Grant (2023-24) | Canada Spends